NCT06663163

Brief Summary

The primary objective of this research is to study the effects of fever on seizure activity in patients with CDKL5 deficiency disorder

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
131

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 27, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 29, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

October 29, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2024

Completed
16 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

April 14, 2026

Status Verified

April 1, 2026

Enrollment Period

2 months

First QC Date

October 27, 2024

Last Update Submit

April 12, 2026

Conditions

Keywords

CDKL5Drug Resistant EpilepsySurvey Research

Outcome Measures

Primary Outcomes (1)

  • Seizure frequency

    The results of seizure reduction reported in the questionnaire completed by the parents or the seizure diary provided online

    Fever episodes within one year leading up to 2 hours of questionnaire completion

Interventions

This study was an observational study without intervention

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Male or female children with a diagnosis of CDKL5 deficiency, including molecular confirmation of a pathogenic or likely pathogenic CDKL5 variant and refractory seizures.

You may qualify if:

  • A diagnosis of CDKL5 deficiency, including molecular confirmation of a pathogenic or likely pathogenic CDKL5 variant and refractory seizures.
  • Parents or guardians are willing to complete and provide information about the child's medical history and fever history after receiving the survey questionnaire online.

You may not qualify if:

  • Any history of previous brain disease (trauma, etc.) that likely to precipitate seizures.
  • Presence of any clinical condition that in the opinion of the principal investigator makes the patient not suitable to participate in the trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xuanwu Hospital,Capital Medical University

Beijing, Beijing Municipality, 100053, China

Location

MeSH Terms

Conditions

CDKL5 deficiency disorderDrug Resistant Epilepsy

Interventions

Observation

Condition Hierarchy (Ancestors)

EpilepsyBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Study Officials

  • Liankun Ren, MD

    Xuanwu Hospital, Beijing

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

October 27, 2024

First Posted

October 29, 2024

Study Start

October 29, 2024

Primary Completion

December 15, 2024

Study Completion

December 31, 2024

Last Updated

April 14, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations